Growing community of inventors

Dragor, Denmark

Joan-Carles Arce

Average Co-Inventor Count = 1.28

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 22

Joan-Carles ArceJane Ruman (3 patents)Joan-Carles ArceAntonio Pellicer-Martinez (1 patent)Joan-Carles ArceCarlos Simon-Valles (1 patent)Joan-Carles ArcePatrick Heiser (1 patent)Joan-Carles ArceRaul Gomez-Gallego (1 patent)Joan-Carles ArceJoan-Carles Arce (11 patents)Jane RumanJane Ruman (3 patents)Antonio Pellicer-MartinezAntonio Pellicer-Martinez (3 patents)Carlos Simon-VallesCarlos Simon-Valles (3 patents)Patrick HeiserPatrick Heiser (2 patents)Raul Gomez-GallegoRaul Gomez-Gallego (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Ferring B.v. (10 from 203 patents)

2. Ferring International Center Sa. (1 from 19 patents)


11 patents:

1. 11752157 - Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

2. 11679145 - Methods of treating infertility

3. 11351228 - Methods of treating infertility

4. 11291708 - Human-derived recombinant FSH for controlled ovarian stimulation

5. 10688106 - Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

6. 10624953 - Human-derived recombinant FSH for controlled ovarian stimulation

7. 10413592 - Methods of treating infertility

8. 10183029 - Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

9. 9694052 - FSH composition and methods for controlled ovarian stimulation

10. 9579305 - Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

11. 8334298 - Treatment or prevention of ovarian hyperstimulation syndrome (OHSS) using a dopamine agonist

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/13/2025
Loading…